8
Participants
Start Date
December 1, 2024
Primary Completion Date
April 1, 2025
Study Completion Date
April 1, 2025
conbercept ophthalmic injection (0.5mg)
Participants were randomly assigned to receive intravitreal injections of either faricimab (IVF, n=4) or conbercept (IVC, n=4) based on a randomisation protocol. To establish a baseline comparison, FVMs were obtained from three treatment-naive patients who served as controls. All participants underwent surgery 4 days after the intravitreal anti-VEGF injections.
Faricimab
According to the randomization protocol, participants were randomly assigned to receive intravitreal injections of faricimab (IVF, n=4) or conbercept (IVC, n=4). To establish a baseline comparison, FVMs were obtained from three treatment-naïve patients as controls. All participants underwent surgery 4 days after intravitreal anti-VEGF injection.
Tianjin medical university eye hosipital, Tianjin
Bojie Hu
OTHER